
Keywords: monogenic diabetes; young type 2 diabetes; personalised medicine; CRP; C-reactive protein; HNF1A; hepatocyte nuclear factor 1 alpha; HNF4A; hepatocyte nuclear factor 4 alpha; HNF1B; hepatocyte nuclear factor 1 beta; GCK; glucokinase; IPSAD; International